Chemomab Therapeutics (CMMB) News Today $3.09 +0.04 (+1.31%) Closing price 04:00 PM EasternExtended Trading$3.09 0.00 (0.00%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest UpdateSeptember 4 at 4:19 AM | americanbankingnews.comChemomab Therapeutics (NASDAQ:CMMB) Stock Price Expected to Rise, Oppenheimer Analyst SaysAugust 29, 2025 | americanbankingnews.comChemomab Therapeutics price target raised to $25 from $10 at OppenheimerAugust 28, 2025 | msn.comChemomab Therapeutics Ltd – ADR trading halted, news pendingAugust 26, 2025 | msn.comChemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 21, 2025 | globenewswire.comCMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South SudanAugust 14, 2025 | globenewswire.comChemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comChemomab Therapeutics Enters Sales Agreement with LifeSci CapitalJuly 28, 2025 | theglobeandmail.comChemomab Therapeutics Announces Positive Phase 2 SPRING Trial Results for Nebokitug as Promising Treatment for Primary Sclerosing Cholangitis at BSG Live’25 - NasdaqJuly 2, 2025 | nasdaq.comChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25July 1, 2025 | finance.yahoo.comChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25June 30, 2025 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)June 14, 2025 | theglobeandmail.comChemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing CholangitisJune 11, 2025 | globenewswire.comChemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing CholangitisJune 3, 2025 | globenewswire.comChemomab Therapeutics Advances Nebokitug for PSC TreatmentMay 16, 2025 | tipranks.comChemomab Hikes on Q1 FiguresMay 15, 2025 | baystreet.caChemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comChemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025May 5, 2025 | globenewswire.comChemomab reports promising PSC treatment dataApril 30, 2025 | uk.investing.comChemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related DiseasesApril 28, 2025 | finance.yahoo.comChemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related DiseasesApril 28, 2025 | globenewswire.comChemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific ConferencesApril 21, 2025 | globenewswire.comChemomab Announces New Medical and Clinical AppointmentsApril 15, 2025 | globenewswire.comChemomab Reports Positive Phase 2 Data For Nebokitug In Primary Sclerosing CholangitisMarch 29, 2025 | nasdaq.comChemomab Therapeutics reports results in nebokitug Phase 2 PSC OLE trialMarch 28, 2025 | markets.businessinsider.comChemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver DiseaseMarch 27, 2025 | benzinga.comChemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver BiomarkersMarch 27, 2025 | globenewswire.comChemomab Therapeutics Updates ADS Offering Under Sales AgreementMarch 20, 2025 | tipranks.comNew Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic SclerosisMarch 6, 2025 | markets.businessinsider.comChemomab Therapeutics announces new scientific presentation on nebokitugMarch 6, 2025 | markets.businessinsider.comNew Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic SclerosisMarch 6, 2025 | globenewswire.comChemomab Therapeutics sees cash runway through 1Q26March 3, 2025 | markets.businessinsider.comChemomab Therapeutics reports Q4 EPS (1c) vs. (1c) last yearMarch 3, 2025 | markets.businessinsider.comChemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate UpdateMarch 3, 2025 | globenewswire.comChemomab Therapeutics price target raised to $7 from $4 at MaximFebruary 20, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)February 20, 2025 | markets.businessinsider.comChemomab completes End-of-Phase 2 Meeting with the FDA for CM-101February 19, 2025 | markets.businessinsider.comChemomab Therapeutics (CMMB) Receives a Buy from OppenheimerFebruary 19, 2025 | markets.businessinsider.comChemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing CholangitisFebruary 19, 2025 | globenewswire.comChemomab Therapeutics Ltd ADRFebruary 12, 2025 | morningstar.comMChemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | markets.businessinsider.comChemomab to Participate in Oppenheimer's Movers in Rare Disease SummitDecember 3, 2024 | globenewswire.comChemomab highlights clincial activity of CM-101 at The Liver Meeting 2024November 20, 2024 | markets.businessinsider.comChemomab Therapeutics Aligns Leadership Incentives with ShareholdersNovember 19, 2024 | markets.businessinsider.comOral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing CholangitisNovember 19, 2024 | globenewswire.comChemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy RatingNovember 15, 2024 | markets.businessinsider.comRoth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)November 15, 2024 | markets.businessinsider.comChemomab Therapeutics sees cash runway through beginning of 2026November 14, 2024 | markets.businessinsider.comChemomab’s Positive Trial Results Boost Investor ConfidenceNovember 14, 2024 | markets.businessinsider.comChemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business UpdateOctober 30, 2024 | markets.businessinsider.com Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMMB Media Mentions By Week CMMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMMB News Sentiment▼0.500.71▲Average Medical News Sentiment CMMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMMB Articles This Week▼21▲CMMB Articles Average Week Get the Latest News and Ratings for CMMB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Chemomab Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PDSB News Today KPTI News Today ICCC News Today DTIL News Today ALXO News Today VTVT News Today CLNN News Today ATNM News Today IMA News Today VRCA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMMB) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMMB Stock Alerts